drugset / Trial / NCT00791102

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102 ↗

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.

Timeline

Start
2010-01
Primary completion
2010-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator ASP-1001 Unknown 0.2 ml Intranasal

Indications